A common childhood virus long suspected of stirring up lupus may be far more involved in the disease than anyone could prove until now.

A new study in the journal Science Translational Medicine is drawing a sharp, mechanistic line between Epstein–Barr virus, or EBV, and the runaway immune reactions that characterise systemic lupus erythematosus.

Lupus is a chronic autoimmune disease. The immune system, which normally protects against infections, loses its sense of self. It starts attacking healthy tissues instead. This can cause painful and sometimes disabling inflammation in many organs. Skin, joints, kidneys, lungs, heart, blood vessels, and brain can all be affected.

People often report extreme fatigue, joint pain, fevers, and the classic butterfly-shaped rash over the cheeks and nose. The condition can flare and then quieten, often unpredictably. Globally, experts estimate that at least 5 million people live with some form of lupus.

Despite decades of research, the root cause of lupus has remained elusive. Genetics clearly play a part. So do hormonal influences. Environmental triggers, such as ultraviolet light, certain medications, and infections, also seem to contribute. Among those triggers, EBV has stood out for many years.

EBV is one of the most common human viruses. It is best known as the cause of glandular fever (also called infectious mononucleosis). Most people encounter EBV in childhood or adolescence.

By adulthood, roughly 95% of people worldwide show evidence of past infection. After the acute illness passes, EBV does not disappear. Instead, it settles quietly into a tiny pool of immune cells known as B cells. These cells normally produce antibodies that target viruses and bacteria. EBV, however, uses them as a hiding place for life.

For decades, epidemiological and immunological data have hinted at a suspicious relationship between EBV and lupus. People with lupus almost always carry antibodies that show prior exposure to EBV.

Many also mount unusually strong immune responses to the virus. Studies have found that people with a history of severe EBV infection, such as glandular fever, have a higher risk of later developing autoimmune diseases, including lupus and multiple sclerosis.

Yet the field lacked a clear, step-by-step biological explanation. Association is not causation. Without a mechanism, EBV’s role in lupus remained a compelling theory, not a confirmed driver.

The new research changes that picture. Scientists at a major academic centre developed an advanced single-cell sequencing technique that finally allowed them to hunt down and examine EBV-infected B cells one by one.

Until now, those cells were almost impossible to study directly. They are extraordinarily rare in the blood of healthy people, and traditional tools could not reliably pick them out from millions of other immune cells.

Using this high-resolution approach, the research team compared blood samples from individuals with lupus to samples from healthy volunteers. In people without lupus, they found that fewer than one in 10,000 B cells carried the latent EBV genome. This tiny reservoir is consistent with past knowledge of the virus’s behaviour.

In stark contrast, in people living with lupus, approximately one in 400 B cells harboured EBV. That is about a 25-fold increase.

That difference surprised the researchers. The absolute numbers remain small, yet the relative increase is enormous. These EBV-infected cells, though rare, appear to act as highly active instigators of autoimmune chaos. Rather than sitting quietly, they become inflammatory leaders.

The study did more than count infected cells. The researchers also looked at which viral and human genes were switched on inside these cells. They discovered that some EBV-infected B cells in lupus express a viral protein known as EBNA2. This protein is a regulatory factor that EBV uses during certain phases of its latent life cycle. EBNA2 can bind to specific regions of the human DNA and alter the activity of host genes.

In lupus, EBNA2 seems to push B cells in a dangerous direction. It activates gene programmes that make the infected B cells more inflammatory and more capable of presenting antigens to other immune cells.

In simple terms, these B cells become overexcited teachers, waving bits of proteins at T cells and shouting that they are threats. Many of these antigens look very much like the body’s own components. The result is the activation of autoreactive T cells and the production of autoantibodies.

These are antibodies directed against self, including DNA, nuclear proteins, and other cellular structures that are hallmarks of lupus.

The study also indicates that EBV does not rely on EBNA2 alone. The virus expresses several other genes in infected B cells, many of which help the cells survive longer, proliferate, and become better at activating immune responses. Together, these viral tools reprogramme B cells into pro-inflammatory drivers of systemic autoimmunity.

One particularly notable finding concerns the type of B cells infected with EBV in lupus. The study shows a striking enrichment of the so-called age-associated B cell phenotype. These cells, despite their name, are not only found in older individuals.

They appear in chronic infections, after certain vaccinations, and prominently in autoimmune diseases. Previous work has linked age-associated B cells to the core autoimmune process in lupus. They often carry autoreactive receptors and are primed to produce autoantibodies. The new findings show that, in lupus, EBV-infected B cells cluster strongly within this exact subset.

Researchers observed that these infected age-associated B cells do more than simply exist. They actively produce autoantibodies and engage in close cross-talk with T cells. By presenting antigens and receiving help signals from T cells, they promote the expansion of further autoreactive B cells.

The study paints a picture of a self-reinforcing loop: EBV reprogrammes a small group of B cells; these cells then ignite and sustain a broad autoimmune cascade characteristic of lupus.

Experts describe the work as an impressive and exciting mechanistic bridge between a common viral infection and a complex, multi-organ autoimmune disease. It steps beyond correlation and narrates a plausible and testable story of cause and effect.

The study also aligns with genetic findings from previous research that linked EBNA2 binding sites to regions of the human genome associated with autoimmune disease risk. Now, that genetic clue finds a cellular counterpart.

This fresh understanding carries important implications for treatment. Current lupus therapies mainly suppress the immune system broadly or target downstream inflammatory pathways.

They can reduce symptoms and prevent organ damage, yet they rarely address any root cause. Many patients still face flares, long-term medication side effects, and significant impact on quality of life.

By highlighting EBV-infected “driver” B cells as a mechanistic engine of disease, the new work suggests a more precise therapeutic target. If clinicians could identify and eliminate these particular cells, it might be possible to interrupt the autoimmune process at its origin.

Such approaches raise an attractive possibility: treatments that are transformative, or even curative, rather than merely palliative. Of course, this remains an aspiration. The road from mechanistic insight in a laboratory to safe, effective therapies for patients is long.

Trials must establish that eliminating EBV-infected driver B cells actually halts disease activity and does so without causing undue harm. The immune system, after all, is intricate and finely balanced. Overly aggressive depletion of B cells can increase infection risk and other complications.

The study also prompts questions that stretch beyond lupus. If EBV is capable of reprogramming B cells to drive autoimmunity in this condition, could similar mechanisms operate in other diseases?

Multiple sclerosis already has a strong epidemiological link to EBV. Rheumatoid arthritis, Sjögren’s syndrome, and other autoimmune disorders have also been associated with previous EBV infection. Researchers now want to know whether EBV-infected B cells in these conditions also produce disease-specific autoantibodies and occupy particular B cell subsets.

Another intriguing angle concerns prevention. If EBV sits at the root of at least some autoimmune diseases, could preventing EBV infection reduce the incidence of those conditions? Experts are keenly interested in the idea of an EBV vaccine.

If scientists could vaccinate children early in life, before natural infection occurs, they might lower the risk of lupus and other EBV-linked diseases in genetically susceptible individuals. Similarly, antiviral therapies that fully suppress EBV activity in those already infected might dampen autoimmune responses.

However, several cautions remain important. Not everyone who gets EBV develops lupus, or any autoimmune disease. In fact, the vast majority do not. Genetics, other infections, hormones, environmental exposures, and chance all shape an individual’s path.

Even in lupus, EBV is likely one crucial piece of a much larger puzzle. The new research strengthens the case that EBV is a central driver in many patients, yet it does not imply that EBV is the sole cause.

For people living with lupus today, this study does not immediately change day-to-day management. Diagnosis still relies on clinical evaluation, blood tests for autoantibodies, and assessment of organ involvement.

Treatment continues to focus on controlling inflammation and preventing damage, using medicines such as hydroxychloroquine, corticosteroids, immunosuppressants, and biologic therapies that target B cells or specific cytokines.

What this work offers is hope for a future where treatments might become more precise and perhaps time-limited, aimed at removing a viral trigger rather than permanently suppressing the immune system.

Next steps for the research team include confirming these findings in larger and more diverse patient cohorts. Longitudinal studies will be especially useful. They may show whether expansion of EBV-infected B cells precedes clinical flares, tracks with disease severity, or predicts response to certain therapies.

Scientists also plan to dissect the molecular details of how EBV reprogrammes autoreactive B cells and to test whether ultra-deep B cell depletion therapies, such as CAR T cell treatments currently under study in severe lupus, work at least in part by targeting EBV-positive driver B cells.

The new study exemplifies the power of modern single-cell technologies. By zooming in on individual immune cells and their viral cargo, researchers can unravel relationships that once seemed unreachable.

For a disease as complex, frustrating, and life-altering as lupus, each such leap in understanding matters. Many patients live for years seeking answers about why their immune system turned against them.

While this research does not yet provide complete answers, it offers something significant: a clearer view of one of the key instigators and a fresh set of ideas for how to fight back.